BR112019007843A2 - métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9) - Google Patents

métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)

Info

Publication number
BR112019007843A2
BR112019007843A2 BR112019007843A BR112019007843A BR112019007843A2 BR 112019007843 A2 BR112019007843 A2 BR 112019007843A2 BR 112019007843 A BR112019007843 A BR 112019007843A BR 112019007843 A BR112019007843 A BR 112019007843A BR 112019007843 A2 BR112019007843 A2 BR 112019007843A2
Authority
BR
Brazil
Prior art keywords
protein
individual
atherosclerotic cardiovascular
pcsk9
subtilisin
Prior art date
Application number
BR112019007843A
Other languages
English (en)
Inventor
Kallend David
Wijngaard Peter
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of BR112019007843A2 publication Critical patent/BR112019007843A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

a presente invenção refere-se a um método de redução do colesterol de lipoproteína de baixa densidade ou prevenção de um evento cardíaco em um indivíduo que tem doença cardiovascular ate-rosclerótica ou equivalente de risco cardiovascular aterosclerótico, envolvendo a administração ao indivíduo de uma quantidade profilaticamente eficaz de um agente de rnai. igualmente, um método de prevenção do desenvolvimento de doença cardiovascular aterosclerótica em um indivíduo envolvendo a administração ao indivíduo de uma quantidade profilaticamente eficaz de um agente de rnai. além disso, um método de tratamento de um indivíduo que tem doença cardiovascular aterosclerótica ou que está em equivalente de risco da doença cardiovascular aterosclerótica envolvendo a administração ao indivíduo de uma quantidade terapeuticamente eficaz de um agente de rnai.
BR112019007843A 2016-10-18 2017-10-18 métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9) BR112019007843A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662409816P 2016-10-18 2016-10-18
US201662422028P 2016-11-14 2016-11-14
US201762472525P 2017-03-16 2017-03-16
US201762550426P 2017-08-25 2017-08-25
PCT/US2017/057218 WO2018075658A1 (en) 2016-10-18 2017-10-18 Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction

Publications (1)

Publication Number Publication Date
BR112019007843A2 true BR112019007843A2 (pt) 2019-10-01

Family

ID=60388127

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007843A BR112019007843A2 (pt) 2016-10-18 2017-10-18 métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)

Country Status (15)

Country Link
US (2) US20180104360A1 (pt)
EP (2) EP4397311A2 (pt)
JP (2) JP7181881B2 (pt)
KR (2) KR20240067272A (pt)
CN (1) CN110088283A (pt)
AU (2) AU2017346879B2 (pt)
BR (1) BR112019007843A2 (pt)
CA (1) CA3042423A1 (pt)
CL (1) CL2019001047A1 (pt)
DK (1) DK3529360T3 (pt)
FI (1) FI3529360T3 (pt)
IL (1) IL266066A (pt)
LT (1) LT3529360T (pt)
MX (1) MX2019004573A (pt)
WO (1) WO2018075658A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114469984A (zh) 2015-08-25 2022-05-13 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
AU2017346879B2 (en) 2016-10-18 2023-11-30 Novartis Ag Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (PCSK9) protein reduction
EP3719127A4 (en) 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CN110997919B (zh) 2017-12-01 2024-04-02 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
JP7436030B2 (ja) 2017-12-29 2024-02-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 複合体及びその調製方法と使用
CN111655849B (zh) 2018-08-21 2024-05-10 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
US20230313195A1 (en) * 2019-05-22 2023-10-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
WO2021185765A1 (en) 2020-03-16 2021-09-23 Argonaute RNA Limited Antagonist of pcsk9
WO2024061157A1 (en) * 2022-09-19 2024-03-28 Kylonova (Xiamen) Biopharma Co., Ltd. Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484588B (zh) * 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
JP6574383B2 (ja) * 2012-12-05 2019-09-11 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＰＣＳＫ９ｉＲＮＡ組成物及びその使用方法
AU2017346879B2 (en) 2016-10-18 2023-11-30 Novartis Ag Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (PCSK9) protein reduction

Also Published As

Publication number Publication date
AU2023263519A1 (en) 2023-12-07
CA3042423A1 (en) 2018-04-26
KR20190077411A (ko) 2019-07-03
AU2017346879B2 (en) 2023-11-30
WO2018075658A1 (en) 2018-04-26
DK3529360T3 (da) 2024-07-15
EP3529360B1 (en) 2024-04-17
LT3529360T (lt) 2024-07-25
US20210093736A1 (en) 2021-04-01
JP2019531357A (ja) 2019-10-31
FI3529360T3 (fi) 2024-07-11
JP7181881B2 (ja) 2022-12-01
CN110088283A (zh) 2019-08-02
JP2022109948A (ja) 2022-07-28
KR20240067272A (ko) 2024-05-16
MX2019004573A (es) 2019-10-07
EP3529360A1 (en) 2019-08-28
CL2019001047A1 (es) 2020-05-08
EP4397311A2 (en) 2024-07-10
IL266066A (en) 2019-06-30
AU2017346879A1 (en) 2019-05-23
US20180104360A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
BR112019007843A2 (pt) métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)
MY195432A (en) Methods For Inhibiting Angiogenesis In A Subject In Need Thereof
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
BR112015000174A2 (pt) método para o tratamento da artrite
BR112015017101A2 (pt) composições de tratamento compreendendo microcápsulas, aminas primárias ou secundárias e sequestrantes de formaldeído
BR112018006445A2 (pt) métodos para tratar distrofia muscular
MX2017005030A (es) Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio.
BR112013028440A2 (pt) composições e métodos que compreendem variantes de serina protease
BR112017004704A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
MX2014013523A (es) Preparaciones de agentes terapeuticos hidrofobos, metodos de elaboracion y uso de los mismos.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
EA201791993A1 (ru) Способы лечения протеинопатий
BR112018013833A2 (pt) métodos de administração de hepcidina
PH12019500422A1 (en) Methods and composition for the prediction of the activity of enzastaurin
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
BR112017007066A2 (pt) composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112014000773A8 (pt) Composições de nicotinamida e uso terapêutico das mesmas
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
BR112017008805A2 (pt) tratamento de córnea usando laminina

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022026853-6 PROTOCOLO 870220122961 EM 28/12/2022 14:30.

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)